These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 27005283)

  • 41. Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study.
    Di Marco V; Giacchino R; Timitilli A; Bortolotti F; Crivellaro C; Calzia R; Iannuzzi C; Prestileo T; Vajro P; Nebbia G; Stringhi C; Rosina F; Biassoni D; Callea F; Rizzetto M; Craxi A
    J Viral Hepat; 1996 May; 3(3):123-8. PubMed ID: 8871870
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
    Deterding K; Wedemeyer H
    AIDS Rev; 2019; 21(3):126-134. PubMed ID: 31532397
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A transient early HBV-DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction.
    Anastasiou OE; Yurdaydin C; Maasoumy B; Hardtke S; Caruntu FA; Curescu MG; Yalcin K; Akarca US; Gürel S; Zeuzem S; Erhardt A; Lüth S; Papatheodoridis GV; Radu M; Liebig S; Bantel H; Bremer B; Manns MP; Cornberg M; Wedemeyer H
    J Viral Hepat; 2021 Feb; 28(2):410-419. PubMed ID: 33185325
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term efficacy of Peg-Interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection.
    Yeh ML; Hsieh MY; Huang CI; Huang CF; Hsieh MH; Huang JF; Dai CY; Chuang WL; Yu ML
    J Gastroenterol Hepatol; 2016 Apr; 31(4):835-41. PubMed ID: 26478984
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatitis D revival.
    Wedemeyer H
    Liver Int; 2011 Jan; 31 Suppl 1():140-4. PubMed ID: 21205152
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An update on HDV: virology, pathogenesis and treatment.
    Alvarado-Mora MV; Locarnini S; Rizzetto M; Pinho JR
    Antivir Ther; 2013; 18(3 Pt B):541-8. PubMed ID: 23792471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of hepatitis delta: Need for novel therapeutic options.
    Abbas Z; Abbas M
    World J Gastroenterol; 2015 Aug; 21(32):9461-5. PubMed ID: 26327754
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].
    Makara M; Horváth G; Gervain J; Pár A; Szalay F; Telegdy L; Tornai I; Ujhelyi E; Hunyady B
    Orv Hetil; 2012 Mar; 153(10):375-94. PubMed ID: 22370225
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study.
    Manesis EK; Vourli G; Dalekos G; Vasiliadis T; Manolaki N; Hounta A; Koutsounas S; Vafiadis I; Nikolopoulou G; Giannoulis G; Germanidis G; Papatheodoridis G; Touloumi G
    J Hepatol; 2013 Nov; 59(5):949-56. PubMed ID: 23850875
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
    Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T
    Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current management of delta hepatitis.
    Rizzetto M
    Liver Int; 2013 Feb; 33 Suppl 1():195-7. PubMed ID: 23286865
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.
    Bogomolov P; Alexandrov A; Voronkova N; Macievich M; Kokina K; Petrachenkova M; Lehr T; Lempp FA; Wedemeyer H; Haag M; Schwab M; Haefeli WE; Blank A; Urban S
    J Hepatol; 2016 Sep; 65(3):490-8. PubMed ID: 27132170
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
    Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
    J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide.
    He W; Ren B; Mao F; Jing Z; Li Y; Liu Y; Peng B; Yan H; Qi Y; Sun Y; Guo JT; Sui J; Wang F; Li W
    PLoS Pathog; 2015 Apr; 11(4):e1004840. PubMed ID: 25902143
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pathogenesis of and New Therapies for Hepatitis D.
    Koh C; Heller T; Glenn JS
    Gastroenterology; 2019 Jan; 156(2):461-476.e1. PubMed ID: 30342879
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D.
    Anastasiou OE; Caruntu FA; Curescu MG; Yalcin K; Akarca US; Gürel S; Zeuzem S; Erhardt A; Lüth S; Papatheodoridis GV; Keskin O; Port K; Radu M; Celen MK; Idilman R; Heidrich B; Mederacke I; von der Leyen H; Kahlhöfer J; von Karpowitz M; Hardtke S; Cornberg M; Yurdaydin C; Wedemeyer H
    Liver Int; 2024 Jan; 44(1):139-147. PubMed ID: 37787009
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients.
    Le Gal F; Gordien E; Affolabi D; Hanslik T; Alloui C; Dény P; Gault E
    J Clin Microbiol; 2005 May; 43(5):2363-9. PubMed ID: 15872267
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular epidemiology of hepatitis D virus circulating in Southwestern Nigeria.
    Opaleye OO; Japhet OM; Adewumi OM; Omoruyi EC; Akanbi OA; Oluremi AS; Wang B; Tong Hv; Velavan TP; Bock CT
    Virol J; 2016 Apr; 13():61. PubMed ID: 27044424
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Resistance of hepatitis delta virus replication to interferon-alpha treatment in transfected human cells.
    Ilan Y; Klein A; Taylor J; Tur-Kaspa R
    J Infect Dis; 1992 Nov; 166(5):1164-6. PubMed ID: 1328404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.